The Personalized Medicine Coalition announces today that its founding president, Edward Abrahams, plans to retire on December 31, 2024, after 20 years of service to the organization. The Coalition intends to hire Slone Partners, a health care and life sciences executive search firm that specializes in personalized medicine, to spearhead the search for Abrahams’ successor.

Abrahams’ tenure with PMC began with the Coalition’s launch by 18 founding member institutions on November 4, 2004, the year after the announcement of the first mapping of a human genome. At the time, there were fewer than five drugs on the market that had biomarker strategies on their respective labels. Today, there are more than 300 personalized medicines and thousands of molecular diagnostic tests that can direct targeted treatments, pointing toward a future in which medicine is personalized, predictive, and preventive.

PMC’s membership includes more than 220 organizations, including diagnostics and biopharmaceutical companies, venture capital firms, clinical care providers, and patient advocacy groups. Its mission is to promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems.

“Under the leadership of Edward Abrahams during the past 20 years, PMC and personalized medicine have gone from being aspirational ideas to revolutionary forces in health care,” said PMC Board Chairman and Culmination Bio CEO Lincoln Nadauld, M.D., Ph.D.

“We envision PMC and personalized medicine becoming even more impactful in the future, and we look forward to selecting a president who shares this vision.”